Cite
Templeton AR, Jeffery PL, Thomas PB, et al. Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. Front Oncol. 2021;11:767697doi: 10.3389/fonc.2021.767697.
Templeton, A. R., Jeffery, P. L., Thomas, P. B., Perera, M. P. J., Ng, G., Calabrese, A. R., Nicholls, C., Mackenzie, N. J., Wood, J., Bray, L. J., Vela, I., Thompson, E. W., & Williams, E. D. (2021). Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. Frontiers in oncology, 11767697. https://doi.org/10.3389/fonc.2021.767697
Templeton, Abby R, et al. "Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management." Frontiers in oncology vol. 11 (2021): 767697. doi: https://doi.org/10.3389/fonc.2021.767697
Templeton AR, Jeffery PL, Thomas PB, Perera MPJ, Ng G, Calabrese AR, Nicholls C, Mackenzie NJ, Wood J, Bray LJ, Vela I, Thompson EW, Williams ED. Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. Front Oncol. 2021 Dec 20;11:767697. doi: 10.3389/fonc.2021.767697. eCollection 2021. PMID: 34988013; PMCID: PMC8721047.
Copy
Download .nbib